TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,018 | -44.0% | 337,614 | -3.7% | 0.03% | -41.2% |
| Q2 2023 | $5,385 | -20.6% | 350,610 | +16.2% | 0.05% | -22.7% |
| Q1 2023 | $6,786 | +33.5% | 301,754 | +24.8% | 0.07% | +26.9% |
| Q4 2022 | $5,084 | -99.9% | 241,734 | -0.9% | 0.05% | -21.2% |
| Q3 2022 | $6,008,000 | +0.6% | 243,838 | -1.1% | 0.07% | +3.1% |
| Q2 2022 | $5,973,000 | -6.8% | 246,526 | -0.9% | 0.06% | +12.3% |
| Q1 2022 | $6,408,000 | -19.2% | 248,671 | -2.7% | 0.06% | -13.6% |
| Q4 2021 | $7,930,000 | +5.3% | 255,476 | -17.7% | 0.07% | -1.5% |
| Q3 2021 | $7,530,000 | +64.0% | 310,518 | -1.3% | 0.07% | +67.5% |
| Q2 2021 | $4,592,000 | -42.8% | 314,749 | -2.0% | 0.04% | -45.9% |
| Q1 2021 | $8,021,000 | -9.3% | 321,234 | -0.9% | 0.07% | -20.4% |
| Q4 2020 | $8,839,000 | – | 324,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |